论文部分内容阅读
[目的]观察经动脉灌注盐酸吉西他滨和奥沙利铂治疗中晚期胰腺癌的临床疗效。[方法]对26例中晚期胰腺癌患者动脉灌注化疗,采用Seldinger法,动脉插管后选择性置管于胰腺癌的供血动脉内,灌注吉西他滨和奥沙利铂,治疗间隔为3周,随访观察临床受益反应(clinical benefit response,CBR)、肿瘤情况和病人的生存时间。[结果]PR9例,SD8例,PD9例。总有效率为34.6%,中位生存时间11个月,临床受益率为65.4%。[结论]盐酸吉西他滨联合奥沙利铂经动脉灌注治疗晚期胰腺癌有肯定的抗癌活性,可能比经静脉滴注能获得更长的生存期和更高的临床受益率。
[Objective] To observe the clinical efficacy of transarterial infusion of gemcitabine hydrochloride and oxaliplatin in the treatment of advanced pancreatic cancer. [Methods] Twenty-six patients with advanced pancreatic cancer undergoing arterial infusion chemotherapy were treated with Seldinger’s method. After arterial catheterization, they were selectively catheterized into the feeding artery of pancreatic cancer. Gestamibine and oxaliplatin were infused. The treatment interval was 3 weeks. Follow- To observe the clinical benefit response (CBR), tumor status and patient’s survival time. [Results] PR9 cases, SD8 cases, PD9 cases. The total effective rate was 34.6%, the median survival time was 11 months, and the clinical benefit rate was 65.4%. [Conclusion] Gemcitabine hydrochloride combined with oxaliplatin via arterial infusion has certain anti-cancer activity in advanced pancreatic cancer, which may result in longer survival time and higher clinical benefit rate than intravenous drip.